Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.50 |
| ▸ | CDC7 | O00311 | 9/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.39 |
| ▸ | CDK9 | P50750 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.39 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4030274 | 0.95 | CDK2 (0.54) | CDK2CDC7MAPK14DYRK3CCNT1 | |
| SCHEMBL4022085 | 0.80 | CDC7 (0.51) | CDK2CDC7MAPK14DYRK3CCNT1 | |
| SCHEMBL6595714 | 0.80 | CDK2 (0.52) | CDK2CDC7DYRK3CCNT1CDK9 | |
| SCHEMBL4020333 | 0.79 | CDC7 (0.53) | CDK2CDC7MAPK14DYRK3CCNT1 | |
| SCHEMBL1447222 | 0.76 | CDK2 (0.53) | CDK2CDC7MAPK14DYRK3CCNT1 | |
| SCHEMBL4022128 | 0.76 | CDK2 (0.47) | CDK2CDC7MAPK14DYRK3CCNT1 | |
| SCHEMBL27534151 | 0.75 | CDC7 (0.54) | CDK2CDC7DYRK3CCNT1CDK9 | |
| SCHEMBL6596348 | 0.74 | DYRK1A (0.46) | CDK2CDC7DYRK3CCNT1CDK9 | |
| SCHEMBL6596886 | 0.73 | DYRK3 (0.40) | CDK2CDC7DYRK3CCNT1CDK9 | |
| SCHEMBL1447097 | 0.73 | CDC7 (0.48) | CDK2CDC7DYRK3CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301928-A1 | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders | AstraZeneca AB (SE) | 2011-03-30 | — | — | EP | disclosed |
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
| EP-1912974-A1 | IMIDAZOLYL-PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007015064-A1 | IMIDAZOLYL-PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | CCNI, MKI67, TYMP | CDK2 13/4885CDC7 112/4885MAPK14 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.